JR Naranjo, H Zhang, D Villar, P González, XM Dopazo, J Morón-Oset, E Higueras, JC Oliveros, MD Arrabal, A Prieto, P Cercós, T González, A De la Cruz, J Casado-Vela, A Rábano, C Valenzuela, M Gutierrez-Rodriguez, J-Y Li, B Mellström
Journal name: 
J Clin Invest
Citation info: 
Deregulated protein and Ca2+ homeostasis underlie synaptic dysfunction and neurodegeneration in Huntington disease (HD); however, the factors that disrupt homeostasis are not fully understood. Here, we determined that expression of downstream regulatory element antagonist modulator (DREAM), a multifunctional Ca2+-binding protein, is reduced in murine in vivo and in vitro HD models and in HD patients. DREAM downregulation was observed early after birth and was associated with endogenous neuroprotection. In the R6/2 mouse HD model, induced DREAM haplodeficiency or blockade of DREAM activity by chronic administration of the drug repaglinide delayed onset of motor dysfunction, reduced striatal atrophy, and prolonged life span. DREAM-related neuroprotection was linked to an interaction between DREAM and the unfolded protein response (UPR) sensor activating transcription factor 6 (ATF6). Repaglinide blocked this interaction and enhanced ATF6 processing and nuclear accumulation of transcriptionally active ATF6, improving prosurvival UPR function in striatal neurons. Together, our results identify a role for DREAM silencing in the activation of ATF6 signaling, which promotes early neuroprotection in HD.
E-pub date: 
01 Feb 2016
Users with this publication listed: 
Diego Villar Lozano